Entrada's Duchenne drug shows disappointing early data, shares tumble

Entrada disclosed initial results from a low‑dose version of its exon‑44 skipping therapy for Duchenne muscular dystrophy. The data, collected from six patients, failed to meet the company’s expectations.

The disappointing readout sent Entrada’s shares down sharply in trading, reflecting investor concern over the program’s near‑term prospects.

In the same briefing, other companies were mentioned – Wegovy’s access was broadened, and updates on BioCryst, GSK and Roche were noted – but the primary market impact stemmed from the Duchenne data.